Vektor Medical has successfully secured $16 million during its Series A funding round. Fueling this investment are co-leaders Solas BioVentures and TVM Capital Life Science, who are placing their bets on Vektor's innovative AI-driven technology for cardiac care.

This financial boost is earmarked for the roll-out of vMap®, its promising non-invasive tool for analyzing arrhythmias. With such strong backing, Vektor is poised to push the boundaries of modern healthcare, transforming the prognosis for patients with heart rhythm disorders.